ABVC Biopharma Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.6% over 5Y.
today you would have $48.92▼ -95.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.13 | $0.59 | $1.16 | $6.25 | $33.90 | $51.00 | $43.70 | $360.00 | $360.00 | $360.00 | $1,433.12 | $2,866.24 | $2,866.24 | $1,433.12 | $25,796.18 | $71,656.05 | |
| P/S | 152.2x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RVPRetractable Technologies Inc | $0.73 | — | 0.3x | — | -4.51% | $21.85M |
| ALLRAllarity Therapeutics, Inc. | $1.41 | — | 6.4x | — | -157.09% | $22.43M |
| BNGOBionano Genomics, Inc. | $1.82 | — | 0.7x | — | -83.56% | $21.43M |
| MRKRMarker Therapeutics, Inc. | $1.37 |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Company description provided by Yahoo Finance.
| 183.1x |
| 18.3x |
| 80.4x |
| 21.3x |
| 288.8x |
| 257.8x |
| 121.4x |
| 61508.5x |
| — |
| — |
| — |
| — |
| 69.9x |
| 12.3x |
| 452.8x |
| 554.5x |
| P/B | 7.9x | 4.9x | 7.6x | 7.9x | 6.7x | 11.6x | 36.2x | — | — | — | — | — | 17.4x | — | — | — | — |
| EPS | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$5.10 | -$5.00 | -$2.10 | -$3.60 | -$3.60 | -$10.80 | — | -$119.52 | $0.00 | -$11,464.97 | -$88,853.50 | -$134,713.38 |
| Profit margin | -3257.63% | -2671.81% | -962.12% | -5109.26% | -1693.50% | -3608.47% | -2193.08% | -560.51% | -87184.16% | — | — | — | — | -2906.79% | -18718.57% | -38202.23% | -12793.14% |
| ROE | -308.10% | -71.17% | -399.86% | -501.13% | -530.02% | -145.18% | -308.10% | — | — | — | — | — | -74.09% | — | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.9x |
| — |
| -76.87% |
| $22.84M |
| LGVNLongeveron Inc. | $6.72 | — | 20.5x | — | -203.61% | $21.42M |
| COCPCocrystal Pharma, Inc. | $1.10 | — | 14.5x | — | -311.68% | $21.19M |